JAK3 IBD

Question 1

Question

Answer 1

Answer

Question 2

Competitor advantages / Disadvantages

Answer 2

Several JAK3 competitors but with other indications, but none selectively inhibit JAK3

Question 3

Pfizer Asset advantages / disadvantages

Answer 3

Pfizer has potential at first in class since no competitors selectively inhibit JAK3

Question 4

Competitors (All MOA)

Answer 4

biologics: Anti-TNFs, Anti-a4b7 (Vedolizumab), Anti p40 (Ustekinumab) and anti-MAdCAM. no highly effective oral therapies available to IBD patients. Pfizer currently developing Tofacitinib for UC (Ph3) , Galapagos / Gilead has Filgotinib (JAK1 inhibitor) in development for Crohn’s (positive POC data presented publically in December 2015). Vedolizumab (Takeda- a4b7 binding antibody) for the treatment of adults with moderate to severe ulcerative colitis and Crohn’s disease approved by FDA and EMA 2014.

Question 5

What phase of development is Pfizer Asset?

Answer 5

Ph1 SAD and MAD, CSR sign off in Aug 2016

Question 6

When/what is next milestone for Pfizer Asset?

Answer 6

PSS December 2016

Question 7

Indication Standard of Care

Answer 7

stepwise treatment with aminosalicylates, antibiotics, corticosteroids, immunomodulators, and clinical trials.

Question 8

Indication Prevalence

Answer 8

over 1 million in US, 2.5 million in EU

Question 9

peak projected sales

Answer 9

xxx